quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:20:04·43d
SECFiling
Olema Pharmaceuticals Inc. logo

SEC Form 144 filed by Olema Pharmaceuticals Inc.

OLMA· Olema Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • OLMA
    Olema Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 27UpdateWolfe Research-
  • Mar 19UpdateJefferies-
  • Feb 11UpdateStifel$48.00
  • Jan 7UpdatePiper Sandler$40.00
  • Oct 8UpdateGuggenheim$20.00
  • Aug 12UpdateCitigroup$21.00

Related

  • PR2d
    Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
  • PR6d
    Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
  • PR21d
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • ANALYST27d
    Wolfe Research initiated coverage on Olema Pharmaceuticals
  • ANALYST35d
    Jefferies resumed coverage on Olema Pharmaceuticals
  • PR37d
    Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
  • SEC38d
    SEC Form 144 filed by Olema Pharmaceuticals Inc.
  • SEC38d
    SEC Form 144 filed by Olema Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022